Get regular updates to your inbox.
The Sumaira Foundation (TSF), a global patient advocacy group focused on neuromyelitis optica spectrum disorder (NMOSD) and a related condition, has presented Tim Walbert, CEO and president of Horizon Therapeutics, its inaugural Global Rare Trailblazer Award. The award was announced in Boston at the foundation’s…
Starting treatment with off-label rituximab soon after neuromyelitis optica spectrum disorder (NMOSD) symptoms begin may prevent long-term disability worsening, a South Korean study suggests. This approach was particularly true for patients who were younger than 50, female, and for those with a severe level of disability before starting rituximab,…
Committee-based assessments are reliable for identifying disease attacks in people with neuromyelitis optica spectrum disorder (NMOSD) in the N-MOmentum clinical trial, which tested the approved therapy Uplizna (inebilizumab-cdon), a new study shows. The study, “Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by…
Brain and spinal cord lesions resolve less often in children with neuromyelitis optica spectrum disorder (NMOSD) than with myelin oligodendrocyte glycoprotein antibody disease (MOGAD), a related disorder, according to a small study. No significant differences in resolving lesions were seen between children with NMOSD and those with multiple…
CCL2, a signaling protein that recruits immune cells to sites of injury, may play a key role in driving the nerve damage that results from antibodies against the aquaporin-4 (AQP4) protein in neuromyelitis optica spectrum disorder (NMOSD), a study suggests. The signaling protein was found to be elevated in…
Out of four markers of nervous system cell injury, blood levels of neurofilament light chain (NfL) were found to best predict disability worsening in people with neuromyelitis optica spectrum disorder (NMOSD), a study showed. Measures of blood NfL levels at the time of an NMOSD attack were the only ones…
Ultomiris (ravulizumab) has been approved by authorities in Japan to prevent relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) positive for antibodies against aquaporin-4 (AQP4). The decision from the Japanese Ministry of Health, Labour and Welfare comes shortly after a similar approval by the European Commission,…
In a racially diverse group of people with neuromyelitis optica spectrum disorder (NMOSD), rituximab worked better to prevent relapses than did oral immunosuppressive therapies, a single-center U.S. study showed. This result was particularly relevant for Black patients — who are usually underrepresented in NMOSD clinical trials but who, the…
The risk of neuromyelitis optica spectrum disorder (NMOSD) attacks following vaccination is low, and such attacks have not been found to be associated with any particular type of vaccine, according to a review study. Also, post-vaccine attacks tended to happen more frequently in men, patients negative for antibodies against…
A small subset of people with neuromyelitis optica spectrum disorder (NMOSD) do not accumulate significant functional disability in the 15 years following symptom onset, according to a recent study. Called benign NMOSD, these patients were more likely to be Caucasian, less likely to have spinal cord involvement at disease…
Get regular updates to your inbox.